Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

COM503

Phase 1Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Neoplasm

NCT06759649

Clinical

Trials by Indication[1]

Neoplasm1 trial

A First-in-Human, Phase 1 Dose Escalation and Dose Expansion Trial to Assess the Safety and Tolerability of COM503 as Monotherapy and in Combination Therapy in Participants With Advanced Solid Malignancies

Recruiting·CCompugen Ltd·Phase 1·NCT06759649·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for COM503. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — COM503 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for COM503. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Compugen Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCompugen Ltd

Related News